Leading pharmaceuticals manufacturer and distributor Sopharma posted a slowdown in terms of net profit, down by 15% YoY to BGN 77.9M. This is mainly due to acquisition of and exemption from subsidiaries in the amount of BGN 36.1 million, as well as the accrued 2022 impairments of non-current assets in the amount of BGN 20.8 million.
Today, on December, 6th 24.75m unused rights in Sopharma’s warrants issue were auctioned on the Bulgarian Stock Exchange (BSE) from 13:15h to 13:45h (local time).
Sopharma Trading, being a wholesaler and retailer of pharmaceuticals, OTC products and cosmetics, is part of the companies at the forefront of the fight against COVID-19.
Current COVID-19 pandemic has already affected all participants in the Bulgarian economy. For Sopharma, this has led to increased demand for specific groups of medicines, including quinin-based medical products for fighting COVID-19, whose export was banned temporarily by the Bulgarian minister of healthcare with the aim of guaranteeing the local needs for this medicine.
Pharma wholesaler Sopharma Trading’s (SO5 BU) consolidated revenues accelerated 6.6% y/y to BGN 465.6m, net profit margin shrank on increased costs in H1’19, according to latest consolidated financials published by the Company.
Leading generic pharma company Sopharma (3JR BU) will not distribute second interim dividend for FY2018, yearly DPS stays BGN 0.05, according to the Company’s GSM invitation scheduled for 7th June, pending approval by the Commercial Register.
Leading generic pharma company Sopharma expanded H1 2018 consolidated top line 21.5% y/y, bottom line down 25.1% on higher costs due to largescale expansion, according to Company’s latest interim financials.
Sopharma Trading boosted its standalone revenue by 8.2% y/y to BGN 352m and expanded bottom line by 13% y/y to BGN 8.1m in H1 2018, according to the Company’s interim financial statements. The top line expansion is a result of increase in all revenue streams of the Company.